Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
about
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@en
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@nl
type
label
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@en
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@nl
prefLabel
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@en
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@nl
P2093
P2860
P1433
P1476
Mutations in DNMT3A, U2AF1, an ...... s with poor outcome after CR1.
@en
P2093
Anjali S Advani
Aziz Nazha
Bartlomiej Przychodzen
Betty K Hamilton
Caner Saygin
Cassandra Hirsch
Christopher Goebel
Donna Abounader
Hetty E Carraway
Jaroslaw P Maciejewski
P2860
P2888
P356
10.1038/S41408-017-0040-9
P577
2018-01-10T00:00:00Z